Alnylam receives more good news on the IP front

Alnylam Pharmaceuticals ($ALNY) received a Notice of Allowance from the U.S. Patent and Trademark Office for an application granting the company new claims to RNA interference (RNAi) medicines. The application, Tuschl '262, covers double-stranded molecules with up to 25 base pairs, and the notice of allowance means the application has survived, according to the U.S. Patent and Trademark Office website. Alnylam is a global leader in RNAi therapeutics and will continue to advance claims in the innovative treatment method, Senior Vice President Laurence Reid said in a statement. The Tuschl '262 is the latest in a family of patents held by the company detailing compositions, uses and delivery methods of RNAi therapeutics. More

Suggested Articles

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

It’s not exactly going to be smooth sailing for Allergan’s multidose bottle version of dry-eye med Restasis. As it finally gets the green light from the FDA, a…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…